Level C· Early human research exploring benefitsProspective StudyPubMed

Identification of Metabolically Distinct Adipocyte Progenitor Cells in Human Adipose Tissues.

Raajendiran A., Ooi G., Bayliss J., O'Brien PE., Schittenhelm RB., Clark AK.

Prospective Study on Type 2 Diabetes, published in Cell Rep (2019) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Cell Rep (2019)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
31042478
DOI
10.1016/j.celrep.2019.04.010

Abstract (original English)

Adipocyte progenitor cells (APCs) provide the reservoir of regenerative cells to produce new adipocytes, although their identity in humans remains elusive. Using FACS analysis, gene expression profiling, and metabolic and proteomic analyses, we identified three APC subtypes in human white adipose tissues. The APC subtypes are molecularly distinct but possess similar proliferative and adipogenic capacities. Adipocytes derived from APCs with high CD34 expression exhibit exceedingly high rates of lipid flux compared with APCs with low or no CD34 expression, while adipocytes produced from CD34 - APCs display beige-like adipocyte properties and a unique endocrine profile. APCs were more abundant in gluteofemoral compared with abdominal subcutaneous and omental adipose tissues, and the distribution of APC subtypes varies between depots and in patients with type 2 diabetes. These findings provide a mechanistic explanation for the heterogeneity of human white adipose tissue and a potential basis for dysregulated adipocyte function in type 2 diabetes.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Abdominal FatAdipocytesAdiposityAdultAnimalsAntigens, CD34Cell ProliferationCells, CulturedDiabetes Mellitus, Type 2Female

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research